Application Notes & Whitepapers 2020
The latest applications and advice from industry experts.
List view / Grid view
The latest applications and advice from industry experts.
Welcome to European Pharmaceutical Review’s Guide to Data Integrity. In this edition, Charles River and Thermo Fisher Scientific showcase their unique data integrity services and discuss how they stand out from the competition.
A new infographic from Study Medicine Europe reveals how blockchain can optimise the healthcare and pharma industries. Here, the information is broken down and discussed.
Mike Owen analyses how smart product information (PIM) management could be crucial in the future of pharma, given how large the industry continues to grow.
A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
The UK’s National Institute for Health and Care Excellence, NICE, recommends the use of fremanezumab on the NHS for preventing chronic migraine.
The pharmaceutical industry is set to greatly benefit from the use of artificial intelligence (AI), due to its wide range of applications. Sydney Tierney discusses how machine learning can enhance marketing, manufacturing and drug trials.
According to renowned data and analytics company GlobalData, India’s phased manufacturing programme will create significant opportunities for medical device manufacturers in India.
The FDA and EMA have accepted licence applications for ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS).
The National Institute for Health and Care Excellence (NICE) has stated that combined use of the drugs pembrolizumab and axitinib is not recommended for untreated advanced renal cell carcinoma in adults.
Voltaren Arthritis Pain has been approved by the FDA as an over-the-counter product for the temporary relief of arthritis pain.
The results of a clinical study for a gestational malaria vaccine has shown that the treatment is "well tolerated" and can produce an immune response.
The EMA’s human medicines committee (CHMP) recommended fifteen medicines for various approvals at its January 2020 meeting; with ten drugs receiving marketing authorisation recommendations and five receiving positive opinions for specific treatments.
Watch Data Scientist Patrick O’Sullivan of Janssen describe how they reduce the amount of time spent preparing data for their million data point systems.
Ten priority actions have been recommended for the European medicines regulatory network to evolve its approach to data use.